NCT01819272已完成2 期
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 240
- 主要终点
- Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks
研究概览
简要总结
This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body weight, and assessed the safety and tolerability of a range of doses of Met DR when administered in subjects with type 2 diabetes mellitus (T2DM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female with T2DM who was ≥18 and ≤65 years of age at Visit 1
- •Had a body mass index (BMI) of 25.0 kg/m² to 45.0 kg/m², inclusive, at Visit 1
- •Screening HbA1c 7.0 to 9.5% (inclusive) at Visit 1 if treated with diet and exercise alone, or 6.0 to 9.5% (inclusive) if on a stable dose of either metformin or DPP-4 inhibitor monotherapy for a minimum of 2 months at Visit 1, or a combination of these 2 agents only on a stable regimen for a minimum of 2 months at Visit 1
- •Had serum creatinine concentration of <1.5 mg/dL (male) or <1.4 mg/dL (female) and an estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation
- •Had a fasting glucose concentration of <280 mg/dL at Visit 1
- •Had a stable body weight, i.e., not varying by >5% for at least 6 months prior to Visit 1 as documented by the investigator
- •Was male, or if female and met all of the following criteria:
- •Not breastfeeding
- •Negative pregnancy test result (human chorionic gonadotropin, beta subunit [βhCG]) at Visit 1 (not applicable to hysterectomized females)
- •If of child bearing potential (including perimenopausal women who have had a menstrual period within 1 year), must have practiced and be willing to continue to practice appropriate birth control during the entire duration of the study
- •Had a physical examination and ECG with no clinically significant abnormalities as judged by the investigator at Visit 1
- •Had no clinically significant laboratory test values (clinical chemistry, hematology, urinalysis) other than those expected in subjects with diabetes as judged by the investigator at Visit 1
- •Either was not treated with or had been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to Visit 1:
- •Hormone replacement therapy (female subjects)
- •Oral contraceptives (female subjects)
- •Antihypertensive agents
- •Lipid-lowering agents
- •Thyroid replacement therapy
- •Antidepressant agents
- •Testosterone therapy (male subjects)
- •If on chronic thyroid pharmacologic therapy, had a serum thyroid-stimulating hormone test result within the normal range at Visit 1
- •Was willing and able to follow study procedures
- •Was able to read, understand, and sign the Informed Consent Form and an Authorization to Use and Disclose Protected Health Information form, answer the study questions, communicate with the investigator, and understand and comply with protocol requirements
排除标准
- •Had a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
- •Hepatic disease
- •Renal disease
- •Gastrointestinal disease
- •Endocrine disorder except T2DM
- •Cardiovascular disease
- •Central nervous system diseases
- •Psychiatric or neurological disorders
- •Organ transplantation
- •Chronic or acute infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus)
- •Orthostatic hypotension, fainting spells or blackouts
- •Allergy or hypersensitivity
- •Clinically significant malignant disease (with the exception of basal and squamous cell carcinoma of the skin) within 5 years of Visit 1
- •Had known hypersensitivity, intolerability, or allergies to metformin HCl or any component of study treatment
- •Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
- •Current drugs or alcohol abuse or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
- •Had major surgery or a blood transfusion within 2 months of Visit 1 or was planning to donate blood during the study, or had a significant blood loss within 2 months prior to Visit 1
- •Had been treated, was being treated, or was expected to require or undergo treatment with any of the following excluded medications:
- •Insulin or sulphonylurea treatment within 3 months of Visit 1
- •GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1
- •Nifedipine within 3 months of Visit 1
- •Systemic corticosteroids by oral, intravenous, intra-articular, or intra-muscular route within 30 days of screening or for more than 1 week within 3 months of Visit 1
- •Prescription weight loss medications within 3 months of Visit 1
- •Chronic or frequent use, in the judgment of the investigator, of any drug treatment that affects gastric pH (prescription or over-the-counter), including proton pump inhibitors or any antacids or medications such as Rolaids or Pepcid within 1 month of Visit 1
- •Had received or planned to receive any iodinated contrast dye within 1 week prior to Visit 1 (Screening)
- •Had a surgical gastrointestinal procedure that may impact the gut hormonal response to study medication
- •History or presence of inflammatory bowel disease or other severe gastrointestinal disease, particularly those which may impact gastric emptying, such as gastroparesis, pyloric stenosis, gastric bypass surgery or gastric banding surgery
- •Had received any investigational drug within 30 days (or five half-lives of the investigational drug, whichever was greater) of Visit 1
- •Was an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or was directly affiliated with the study at the clinical study site
- •Was employed by Elcelyx Therapeutics, Inc. (that is an employee, temporary contract worker, or designee responsible for the conduct of the study)
研究组 & 干预措施
600 mg DR
Experimental
600 mg delayed-release metformin once daily in the morning
干预措施: Met DR (Drug)
800 mg DR
Experimental
800 mg delayed-release metformin once daily in the morning
干预措施: Met DR (Drug)
1000 mg DR
Experimental
1000 mg delayed-release metformin once daily in the morning
干预措施: Met DR (Drug)
1000 mg XR
Active Comparator
1000 mg extended-release metformin once daily in the evening
干预措施: Met XR (Drug)
2000 mg XR
Active Comparator
2000 mg extended-release metformin once daily in the evening
干预措施: Met XR (Drug)
Placebo
Placebo Comparator
Placebo once daily in the morning
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks
时间窗: Baseline and 4 weeks after the first dose of study medication
次要结局
- Change in HbA1c (%) at 12 Weeks(Baseline and 12 weeks after the first dose of study medication)
- AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks(Baseline and 4 to 12 weeks after the first dose of study medication)
研究者
相似试验
已完成
2 期
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DMType 2 Diabetes MellitusNCT02526524Elcelyx Therapeutics, Inc.571
已完成
1 期
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DMType 2 Diabetes MellitusNCT01804842Elcelyx Therapeutics, Inc.26
已完成
1 期
Assessing the PK of Met DR, Met IR, and Met XR in Healthy SubjectsHealthy SubjectsNCT02291510Elcelyx Therapeutics, Inc.20
Unknown
不适用
Extended-release vs Immediate-release Metformin in PCOS WomenPolycystic Ovary SyndromeNCT02984722Catholic University of the Sacred Heart80
撤回
不适用
Prospective Trial of Metformin - Chemoprevention RoleColorectumNCT01550900M.D. Anderson Cancer Center